1. Home
  2. CRSP vs ENS Comparison

CRSP vs ENS Comparison

Compare CRSP & ENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CRSP

CRISPR Therapeutics AG

N/A

Current Price

$55.44

Market Cap

5.8B

Sector

Health Care

ML Signal

N/A

Logo EnerSys

ENS

EnerSys

N/A

Current Price

$189.59

Market Cap

6.8B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
CRSP
ENS
Founded
2013
1991
Country
Switzerland
United States
Employees
N/A
9200
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Industrial Machinery/Components
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
6.8B
IPO Year
2016
2004

Fundamental Metrics

Financial Performance
Metric
CRSP
ENS
Price
$55.44
$189.59
Analyst Decision
Buy
Buy
Analyst Count
22
5
Target Price
$87.56
★ $252.58
AVG Volume (30 Days)
★ 1.3M
383.0K
Earning Date
11-09-2026
11-04-2026
Dividend Yield
N/A
★ 0.63%
EPS Growth
N/A
★ N/A
EPS
N/A
★ 3.09
Revenue
★ $289,590,000.00
$216,125,000.00
Revenue This Year
$1,063.30
$3.87
Revenue Next Year
$283.48
$4.87
P/E Ratio
★ N/A
$59.24
Revenue Growth
★ 9169.85
15.85
52 Week Low
$44.12
$108.88
52 Week High
$78.48
$244.30

Technical Indicators

Market Signals
Indicator
CRSP
ENS
Relative Strength Index (RSI) 52.39 50.41
Support Level $50.56 $175.64
Resistance Level $60.04 $182.19
Average True Range (ATR) 2.83 3.81
MACD -0.03 1.34
Stochastic Oscillator 51.06 79.79

Price Performance

Historical Comparison
CRSP
ENS

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About ENS EnerSys

EnerSys provides stored energy solutions for industrial applications. It also manufactures and distributes energy systems solutions and motive power batteries, specialty batteries, battery chargers, power equipment, battery accessories, and outdoor equipment enclosure solutions to customers. Energy Systems that combine enclosures, power conversion, power distribution, and energy storage are used in the telecommunication and broadband, utility industries, uninterruptible power supplies, and numerous applications requiring stored energy solutions. Its segments include Energy Systems, Motive Power, New Ventures, and Specialty.

Share on Social Networks: